Skip to main content
. 2024 May 24;15:1409506. doi: 10.3389/fphar.2024.1409506

TABLE 1.

Summary of NCI-60 cancer cell panel screening results.

Panel/Cell line GI50 LC50
Leukemia
CCRF-CEM 1.05E-06 > 1.00e-4
HL-60(TB) 1.93E-06 > 1.00e-4
K-562 2.36E-06 > 1.00e-4
MOLT-4 2.71E-06 > 1.00e-4
SR 3.50E-08 > 1.00e-4
Non-Small Cell Liung Cancer
A549/ATCC 1.64E-05 > 1.00e-4
EKVX 1.31E-05 6.05E-05
HOP-62 3.10E-06 3.00E-05
HOP-92 2.38E-06 1.44E-05
NCI-H226 3.21E-06 > 1.00e-4
NCI-H23 3.31E-06 > 1.00e-4
NCI-H322M 1.36E-05 6.24E-05
NCI-H460 3.74E-06 > 1.00e-4
*NCI-H522 1.72E-06 6.43E-06
Colon Cancer
*COLO 205 1.24E-06 6.69E-06
*HCC-2998 2.12E-06 8.70E-06
*HCT-116 1.97E-06 7.65E-06
HCT-15 1.93E-06 n/a
HT29 2.33E-06 > 1.00e-4
KM12 3.51E-06 5.00E-05
SW-620 1.60E-06 > 1.00e-4
CNS Cancer
SF-268 2.32E-06 > 1.00e-4
SF-295 1.54E-05 5.74E-05
SF-539 2.42E-06 > 1.00e-4
SNB-19 1.06E-05 > 1.00e-4
SNB-75 2.67E-05 > 1.00e-4
U251 1.16E-05 5.51E-05
Prostate Cancer
PC-3 2.52E-06 7.76E-05
DU-145 1.39E-06 n/a
Panel/Cell line GI50 LC50
Melanoma
LOX IMVI 9.76E-07 > 1.00e-4
MALME-3M 2.31E-06 > 1.00e-4
*M14 1.90E-06 8.80E-06
*MDA-MD-435 1.92E-06 9.17E-06
SK-MEL-2 1.30E-05 5.53E-05
*SK-MEL-28 1.83E-06 7.17E-06
SK-MEL-5 3.54E-06 3.78E-05
UACC-357 2.98E-06 3.14E-05
*UACC-62 1.75E-06 7.96E-06
Ovarian Cancer
OVCAR-3 1.04E-06 n/a
OVCAR-4 3.51E-06 4.78E-05
OVCAR-5 4.55E-06 9.40E-05
OVCAR-8 3.36E-06 > 1.00e-4
NCI/ADR-RES 3.01E-06 > 1.00e-4
SK-OV-3 1.66E-05 5.59E-05
Renal Cancer
*786-O 1.79E-06 6.55E-06
A498 1.55E-05 5.44E-05
ACHN 1.46E-06 1.46E-05
CAKI-1 1.41E-06 5.32E-05
*RXF 393 1.73E-06 6.17E-06
SN12C 1.93E-06 n/a
*TK-10 1.49E-06 5.79E-06
*UO-31 1.57E-06 6.33E-06
Breast Cancer
MCF7 1.17E-06 > 1.00e-4
HS 578T 3.78E-06 > 1.00e-4
BT-549 2.38E-06 2.68E-05
T-47D 1.27E-06 > 1.00e-4
MDA-MB-468 1.61E-06 > 1.00e-4

50/60 (83.3%) GI50 < 4.55 mM; 12/60 (20%) LC50 < 10 mM.